Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Health topic
No spam. Unsubscribe anytime.
Senate endorses program to expand epinephrine access, then tables the bill for fiscal review
Summary
Senator Kennedy won wide floor support for HB206, a plan to expand access to epinephrine auto-injectors via a post-rebate program, but the Senate voted to table the bill on third reading pending a fiscal note.
The Senate debated House Bill 206 on Feb. 11, a measure designed to make epinephrine auto-injectors more affordable and widely available by leveraging a post-rebate purchasing program. Senator Kennedy told colleagues that anaphylaxis can kill within minutes and that the bill builds on prior work to reduce prices on essential medicines for Utahns. "This bill... makes it financially feasible for individuals to obtain this life saving medicine," Kennedy said on the floor.
The bill was reported on a third-reading roll call with unanimous or near-unanimous support, but Senator Ibsen moved to table HB206 on third reading to secure a fiscal note; the motion to table passed and the bill was placed on hold pending fiscal analysis. Supporters emphasized the public-health importance of broader access to epinephrine, whereas senators who moved the tabling asked for a cost estimate before final enrollment.
Next steps: Legislative fiscal staff will prepare a fiscal note; final disposition of HB206 will depend on that analysis and any subsequent floor action.
